- Home
- AVTX vs PYXS Comparison
AVTX vs PYXS Comparison
Compare AVTX & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- PYXS
- Stock Information
- Founded
- AVTX 2011
- PYXS 2018
- Country
- AVTX United States
- PYXS United States
- Employees
- AVTX N/A
- PYXS N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- PYXS Biotechnology: Pharmaceutical Preparations
- Sector
- AVTX Health Care
- PYXS Health Care
- Exchange
- AVTX Nasdaq
- PYXS Nasdaq
- Market Cap
- AVTX 88.4M
- PYXS 76.1M
- IPO Year
- AVTX 2015
- PYXS 2021
- Fundamental
- Price
- AVTX $8.44
- PYXS $1.28
- Analyst Decision
- AVTX Strong Buy
- PYXS Strong Buy
- Analyst Count
- AVTX 4
- PYXS 6
- Target Price
- AVTX $33.00
- PYXS $9.20
- AVG Volume (30 Days)
- AVTX 36.6K
- PYXS 539.7K
- Earning Date
- AVTX 03-28-2025
- PYXS 03-20-2025
- Dividend Yield
- AVTX N/A
- PYXS N/A
- EPS Growth
- AVTX N/A
- PYXS N/A
- EPS
- AVTX N/A
- PYXS N/A
- Revenue
- AVTX $820,000.00
- PYXS $16,146,000.00
- Revenue This Year
- AVTX N/A
- PYXS N/A
- Revenue Next Year
- AVTX N/A
- PYXS N/A
- P/E Ratio
- AVTX N/A
- PYXS N/A
- Revenue Growth
- AVTX N/A
- PYXS N/A
- 52 Week Low
- AVTX $4.24
- PYXS $1.23
- 52 Week High
- AVTX $34.46
- PYXS $6.85
- Technical
- Relative Strength Index (RSI)
- AVTX 57.77
- PYXS 32.91
- Support Level
- AVTX $6.81
- PYXS $1.23
- Resistance Level
- AVTX $8.00
- PYXS $1.40
- Average True Range (ATR)
- AVTX 0.56
- PYXS 0.09
- MACD
- AVTX 0.03
- PYXS 0.00
- Stochastic Oscillator
- AVTX 81.99
- PYXS 15.15
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About PYXS Pyxis Oncology Inc.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.